WARRANTS TO PURCHASE COMMON STOCK

3 Months Ended

Mar. 31, 2026

NOTE 14 – WARRANTS TO PURCHASE COMMON STOCK

The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at March 31, 2026:

Exercise		Number			Expiration
Price		Outstanding			Date
$	0.001		615,025	⁽¹⁾	December 2030
$	1,056.00		4,585		April 2029
$	1,056.00		2,782		April 2029
$	1,056.00		2,172		April 2029
$	1,056.00		10,884		April 2029
$	1,600.00		36		October 2028
$	2,720.00		5,758		December 2028
$	3,200.00		22		August 2028
			641,264

(1)

Represents prefunded warrants.

During the three months ended March 31, 2025, warrants totaling 10,884 became exercisable, 5,758 became exercisable upon FDA acceptance of our NDA filing, and 1, with an exercise price of $1,056, $1,776 and $364,800, respectively, expired.